CHK2 / CHEK2 Antibody (Antigen Affinity Purified)

CHK2 / CHEK2 Antibody ( Antigen Affinity Purified ) Datasheet

CHK2 / CHEK2 Antibody Product Information

• Immunogen: Recombinant Mouse CHK2 / CHEK2 protein (Catalog#50432-M20B)
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Mouse CHK2 / CHEK2 (rM CHK2 / CHEK2; Catalog#50432-M20B; Q9Z265; Mey1-Leu 546). CHK2 / CHEK2 specific IgG was purified by Mouse CHK2 / CHEK2 affinity chromatography.

CHK2 / CHEK2 Antibody Usage Guide

• Specificity: Mouse CHK2 / CHEK2
• Immunochemistry: IHC-P: 0.1-2 μg/mL

  

  Immunochemical staining of mouse CHEK2 in mouse spleen with rabbit polyclonal antibody (1 μg/mL, formalin-fixed paraffin embedded sections).

• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

CHK2 / CHEK2 Antibody Background

Serine / threonine-protein kinase Chk2, also known as Cds1 and CHEK2, is a nucleusprotein which belongs to theprotein kinase superfamily, CAMK Ser/Thr protein kinase family and CHK2 subfamily. CHEK2 regulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. CHEK2 inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. CHEK2 may also play a role in meiosis. CHEK2 regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'. Defects in CHEK2 are associated with Li-Fraumeni syndrome 2 which is a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53 / TP53. Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) which is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

References

1. Matsuoka S. et al., 1998, Science. 282: 1893-1897.
2. Li J. et al.,2002, Mol Cell. 9: 1045-1054.
3. Staalesen V. et al., 2004, Oncogene. 23: 8535-44.
4. Kilpivaara O. et al., 2004, Int J Cancer. 111: 543-7.
5. Petrinac S. et al., 2009, Cell Cycle. 8: 327-9.